Absence of post-treatment changes in sentinel lymph nodes does not translate into increased regional recurrence rate in initially node positive breast cancer patients

Abstract

Abstract Purpose: To determine whether the absence of post-treatment changes in the negative sentinel lymph nodes (SLN) in the neoadjuvant setting for biopsy-proven cN+ disease results in an increased regional recurrence (RR) rate in patients after SLN biopsy (SLNB) only. Methods: Breast cancer patients with biopsy-proven cN+ disease who converted to node-negative disease after neoadjuvant systemic treatment (NAST) and underwent SLNB only were included. Retrospective analysis was performed for patients diagnosed between 2008 and 2021. Patohistological specimens were reviewed for the presence of post-treatment changes in the SLNs. Patients with negative SLNs (ypN0) were divided into 2 groups: i) with post-treatment changes, ii) without post-treatment changes. Patients' characteristics were compared between groups. Crude RR rates were compared using the log-rank test. Recurrence-free (RFS) and overall survival (OS) for the entire cohort were calculated using Kaplan-Meier. Results: Of 437 patients with cN+ disease, 95 underwent SLNB only. 82 were ypN0, 57 with post-treatment changes (group 1), 30 without post-treatment changes (group 2). During the median follow-up of 37 months (range 6–148), 1 isolated regional recurrence occurred in group 2 (RR rate 0% for group 1 vs. 4% for group 2, p=0.167). 3-year RFS and 3-year OS were 90.2% and 96.3%, respectively. Conclusion: Absent post-treatment changes in negative SLNs for biopsy-proven cN+ disease that covert to node-negative after NAST did not result in increased regional recurrence rates in our cohort. Multidisciplinary input is essential to determine whether additional treatment is needed in these patients.